CYCLOSPORIN A IN RHEUMATOID ARTHRITIS

环孢素A每日口服治疗的疗效和毒性 活动期类风湿性关节炎将在6个月内接受评估 低剂量(1 mg/kg/d)与高剂量(10 mg/kg/d)的双盲研究 CsA。毒性在前两个月每周监测一次，然后每两个月监测一次 几周到6个月。疾病活动每两个月进行一次评估。 疾病活动性改善不到40%的患者 6个月大的孩子会被排除在研究之外，而那些年龄在40%或更高的孩子 持续6个月的药物治疗。其影响 环孢素A对外周血T淋巴细胞功能各项指标的影响 对所有患者的滑膜内进行了研究。

The efficacy and toxicity of daily, oral cyclosporin A (CSA) in patients with active rheumatoid arthritis is being evaluated in a 6 month double-blind study of low dose (1mg/kg/day) versus high dose (10mg/kg/day) CSA. Toxicity is monitored weekly for the first 2 months and then every 2 weeks until 6 months. Disease activity is assessed on a bi-monthly basis. Patients who do not develop at least a 40% improvement in disease activity at 6 months are dropped from the study, while those with a 40% or greater response continue for an additional 6 months of drug therapy. The effects of CSA on various measures of T lymphocyte function in peripheral blood and within the synovium is studied in all patients.